Glenmark Specialty
-
Glenmark receives US FDA nod for GRC 54276 to treat advanced solid tumours and lymphomas
GRC 54276 is an orally available, small-molecule hematopoietic progenitor kinase 1 (HPK1) inhibitor Glenmark Specialty, the subsidiary of Glenmark Pharmaceuticals,…
Read More » -
Bausch Health, Glenmark bags RYALTRIS approval in Canada
RYALTRIS treats moderate to severe seasonal allergic rhinitis (SAR) and associated ocular symptoms in adults, adolescents, and children aged sixyears…
Read More » -
Glenmark Specialty Switzerland receives NDA approval for Ryaltris Nasal Spray
Ryaltris will be marketed and distributed in the US by Hikma Specialty USA Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical…
Read More »
